Phase 3 LUNAR Clinical Trial Results to Be Presented at WCLC 2024

Novocure, a global oncology company, will highlight novel Tumor Treating Fields (TTFields) at the upcoming International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on Lung Cancer (WCLC), according to a press release.

Nicolas Leupin, MD, Chief Medical Officer of Novocure, expressed his eagerness to share “new analyses with the lung cancer community,” in the press release. “With multiple regulatory reviews underway, there is no better time to examine the promise of TTFields use in the treatment of [non-small cell lung cancer (NSCLC)].”

TTFields are “electric fields that exert physical forces to kill cancer cells via a variety of mechanisms,” according to the statement from Novocure.

Novocure will highlight the phase 3 LUNAR clinical trial at the conference, which evaluated TTFields therapy combined with the standard of care for metastatic NSCLC after platinum-based therapy.

According to the analysis, “a statistically significant and clinically meaningful extension in [overall survival (OS)] for patients treated with TTFields and standard systemic therapies, as well as a pronounced extension in OS for patients randomized to receive physician’s choice immune checkpoint inhibitor together with TTFields” was identified. Therefore, the LUNAR trial met its primary endpoint.

Additionally, in a recent post-hoc analysis, researchers from Novocure evaluated survival data from both LUNAR and a simulation study assessing “the effect of body mass index (BMI) on [OS] and the feasibility of delivering TTFields at a therapeutic intensity to patients of varying BMIs,” according to the press release from Novocure.

No OS differences were observed in the post-hoc analysis between patients with a BMI above and below <25 kg/m ². Furthermore, the simulation-based study “suggests TTFields can be delivered to the lungs in therapeutic dose and a corresponding clinical benefit observed in patients across a range of BMIs,” according to the research team.

In addition to the post-hoc analysis of LUNAR and the simulation study, Novocure will have seminars, posters, and discussions at IASLC 2024 WCLC, including the following:

• Sunset Seminar: Women in Thoracic Oncology
• Impact of BMI on TTFields in Patients with mNSCLC: Post-hoc Analysis from the Phase 3 LUNAR Study and Simulation Model Data
• Treatment of Non-Small Cell Lung Carcinoma (NSCLC) Cells With Tumor Treating Fields (TTFields) and DNA-Dependent Protein Kinase (PK) Inhibitors
• Tumor Treating Fields (TTFields) Induce Pro-Inflammatory Phenotype Skewing of Macrophages

The IASLC 2024 WCLC will take place from September 7-10, 2024, in San Diego, California.

Source: Novocure